PARIS (Reuters) – Healthcare and clinical diagnostics company Novacyt, whose shares have surged on the back of its COVID-19 testing products, on Thursday announced the launch of three new products to support testing for the presence of the virus.

The names of the new products are Exsig™ Direct, Exsig™ Mag and COVID-HT, Novacyt said.

The announcement of Novacyt’s latest COVID-19 testing products pushed the company’s Paris-listed shares up by around 10% by 0710 GMT, with the stock having jumped by around 1,600% since the start of 2020.

“As we continue to supply our COVID-19 test to laboratories around the world, we are delighted to provide further support through the launch of these new products,” CEO Graham Mullis said.

Novacyt has singled itself out with a test able to detect the new coronavirus in less than two hours. Standard testing, which also identifies other strains, takes up to a day.